{
  "source": "PA-Med-Nec-Sohonos.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2024 P 2322-2\nProgram Prior Authorization/Medical Necessity\nMedication Sohonos™ (palovarotene)\nP&T Approval Date 1/2024, 10/2024\nEffective Date 1/1/2025\n1. Background:\nSohonos (palovarotene) is a retinoid indicated for reduction in the volume of new heterotopic\nossification in adults and children aged 8 years and older for females and 10 years and older for\nmales with fibrodysplasia ossificans progressiva (FOP).\n2. Coverage Criteriaa:\nA. Initial Authorization\n1. Sohonos will be approved based on all of the following criteria:\na. Diagnosis of fibrodysplasia ossificans progressiva (FOP)\n-AND-\nb. Diagnosis has been confirmed by the presence of a mutation in the activin receptor IA\n(ACVR1) gene\n-AND-\nc. One of the following:\n(1) Both of the following:\n(a) Patient is female\n(b) Patient is aged 8 years and older\n-OR-\n(2) Both of the following:\n(a) Patient is male\n(b) Patient is aged 10 years and older\n-AND-\nd. Sohonos is being used to reduce the volume of new heterotopic ossification (HO)\n-AND-\n© 2024 UnitedHealthcare Services, Inc.\n1\ne. Prescribed by or in consultation with an FOP expert (e.g., endocrinologist, geneticist,\npediatric orthopedist, pediatric rheumatologist)\nAuthorization will be issued for 12 months.\nB. Reauthorization\n1. Sohonos will be approved based on both of the following criteria:\na. Documentation of positive clinical response (e.g., reduction in new HO volume,\nimproved CAJIS and FOP-PFQ scores, improved quality of life)\n-AND-\nb. Prescribed by or in consultation with an FOP expert (e.g., endocrinologist, geneticist,\npediatric orthopedist, pediatric rheumatologist)\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific benefit\nplan coverage may also impact coverage criteria. Other policies and utilization management\nprograms may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHe",
    "cific benefit\nplan coverage may also impact coverage criteria. Other policies and utilization management\nprograms may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by program\nand/or therapeutic class\n4. References:\n1. Sohonos [package insert]. Cambridge, MA: Ipsen Biopharmaceuticals, Inc.; August 2023.\n2. The International Clinical Council (ICC) on Fibrodysplasia Ossificans Progressiva (FOP).\nThe medical management of fibrodysplasia ossificans progressiva: current treatment\nconsiderations. July 2024. Available at: Guidelines | International Clinical Council (ICC) on\nFibrodysplasia Ossificans Progressiva (FOP) (iccfop.org). Accessed on August 29, 2024.\nProgram Prior Authorization/Medical Necessity - Sohonos (palovarotene)\nChange Control\n1/2024 New program.\n10/2024 Annual review with no changes to coverage criteria. Updated\nreferences.\n© 2024 UnitedHealthcare Services, Inc.\n2"
  ]
}